EClinicalMedicine, a clinical journal by The Lancet has published the results from the Telerobotic Intervention Study, the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catherization lab using Corindus’s CorPath technology platform.
An internationally acclaimed physician Dr. Tejas Patel, Chairman and Chief Interventional Cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India performed elective PCI procedures using CorPath GRX Robotic System technology on five patients from a distance of approximately 20 miles (32 kilometers) from Dr. Patel’s location inside the Swaminarayan Akshardham Temple in Gandhinagar, Gujarat, India, while his partner Dr. Sanjay Shah, was onsite in the room with each patient at the Apex Heart Institute.
“I am honoured to have been a part of this medical milestone,” stated Dr. Patel. “The application of telerobotics for remote treatment has the potential to impact a significant number of lives by providing access to specialized care that may not otherwise be possible. I am pleased to share my experience with the clinical community in such a well-respected publication that is part of the Lancet family,” added Dr. Patel.
Corindus has pioneered the world’s first remote telerobotic intervention platform for delivering highly specialized and timely cardiovascular care to underserved patient populations with geographic barriers to treatment. The aim of the company is to expand its robotic platform to address stroke care.
“Remote procedures have the potential to transform how we deliver care when treating the most time-sensitive illness such as heart attack and stroke. The success of this study paves the way for large-scale, ling-distance telerobotic platforms across the globe, and its publication in Lancet’s EClinicalMedicine demonstrates the transformative nature of telerobotics,” said Mark Toland, President and Chief Executive Officer of Corindus Vascular Robotics. “While remote robotic procedures are still in the early stages of development, it is clear we are on track to expand patient’s access to care, while reducing their time to treatment,” Toland concluded.